Cuts to federal research funding may delay a potential hepatitis B cure, as trials led by UCSF progress. Asian Americans ...

Hepatitis B virus-induced hepatocellular carcinoma (HCC) remains a major global health burden, and new therapeutic and ...

Cellular aging may explain persistent liver stiffness after HCV eradication, with shorter telomeres linked to poorer hepatic ...

AbbVie just scored an FDA win as its antiviral drug Mavyret received label expansion to treat acute Hepatitis C. The FDA ...

AbbVie Inc. (NYSE:ABBV) is one of the 12 best healthcare stocks to buy now. On June 12, the US Food and Drug Administration ...

New data from the Centers for Disease Control and Prevention shows Oregon is third worst in the nation for deaths from ...

The study was conducted for over five years in the Department of Medical Gastroenterology, PGIMS, Rohtak, and included 5,400 ...

A Supreme Court decision that could overturn the Affordable Care Act’s coverage mandate for preventive health screenings ...

The FDA approved Mavyret for the treatment of patients 3 years and older with acute or chronic HCV infection without cirrhosis or with compensated cirrhosis.

AbbVie has received approval from the U.S. Food and Drug Administration (FDA) for a label expansion for MAVYRET ...

AbbVie’s Mavyret receives US FDA label expansion approval for treatment of chronic hepatitis C virus: North Chicago Saturday, June 14, 2025, 11:00 Hrs [IST] AbbVie announced tha ...

FDA approved a label expansion for Mavyret for the treatment of acute hepatitis C virus, according to a press release from the manufacturer, AbbVie.